The Latest Cardiac and Vascular News
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrential Tricuspid Regurgitation. The Trans-Jugular TTVR procedure was performed on November 21, 2022, on compassionate grounds […]
TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVC Expect to submit TN-401 IND application to the FDA in 2023 SOUTH SAN FRANCISCO, […]
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability […]
U.S. Clinical Trial Commencement Anticipated in 1Q2023 BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece aortic valve shaped to mimic the native human valve, today announced the U.S. Food and Drug Administration (FDA) has conditionally approved […]
Financing co-led by Vensana Capital and a Large, Global Medical Device Company Use of Proceeds to Advance Development of a Novel Catheter-based Solution for Mitral Regurgitation ATLANTA, Nov. 23, 2022 /PRNewswire/ — Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the […]
PARIS–(BUSINESS WIRE)–Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants of its Aeson® artificial heart is now effective On October […]
DUBLIN, Ireland–(BUSINESS WIRE)–CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve technology for the treatment of Tricuspid Regurgitation as part of its TANDEM I study in Poland. The procedures were performed as part of an ongoing clinical trial at the National Institute of Cardiology, […]
VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal – Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy […]
New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of virtual cardiologists and care NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, and Heartbeat Health, the nation’s largest virtual-first cardiovascular company, today announced a partnership to […]
